These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26176326)

  • 1. Awareness of the Food and Drug Administration's Bad Ad Program and Education Regarding Pharmaceutical Advertising: A National Survey of Prescribers in Ambulatory Care Settings.
    O'Donoghue AC; Boudewyns V; Aikin KJ; Geisen E; Betts KR; Southwell BG
    J Health Commun; 2015; 20(11):1330-6. PubMed ID: 26176326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting and Reporting Deceptive Prescription Drug Promotion: Differences Across Consumer and Physician Audiences and by Number and Type of Deceptive Claims and Tactics.
    Betts KR; O'Donoghue AC; Johnson M; Boudewyns V; Paquin RS
    Health Commun; 2022 Nov; 37(13):1609-1621. PubMed ID: 33840305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What influences healthcare providers' prescribing decisions? Results from a national survey.
    Price SM; O'Donoghue AC; Rizzo L; Sapru S; Aikin KJ
    Res Social Adm Pharm; 2021 Oct; 17(10):1770-1779. PubMed ID: 33558154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.
    Faerber AE; Kreling DH
    J Gen Intern Med; 2014 Jan; 29(1):110-8. PubMed ID: 24030427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of misleading information in prescription drug television advertising: The roles of advertisement similarity and time delay.
    Aikin KJ; Southwell BG; Paquin RS; Rupert DJ; O'Donoghue AC; Betts KR; Lee PK
    Res Social Adm Pharm; 2017; 13(2):378-388. PubMed ID: 27178746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State variability in supply of office-based primary care providers: United States, 2012.
    Hing E; Hsiao CJ
    NCHS Data Brief; 2014 May; (151):1-8. PubMed ID: 24813076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concern about the Expanding Prescription Drug Epidemic: A Survey of Licensed Prescribers and Dispensers.
    Wright RE; Reed N; Carnes N; Kooreman HE
    Pain Physician; 2016 Jan; 19(1):E197-208. PubMed ID: 26752487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
    Schwartz LM; Woloshin S; Lu Z; Ross KM; Tessema FA; Peter D; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006073. PubMed ID: 31707825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H
    Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013.
    Johnson NB; Hayes LD; Brown K; Hoo EC; Ethier KA;
    MMWR Suppl; 2014 Oct; 63(4):3-27. PubMed ID: 25356673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advance directives among health care professionals at a community-based cancer center.
    Go RS; Hammes BA; Lee JA; Mathiason MA
    Mayo Clin Proc; 2007 Dec; 82(12):1487-90. PubMed ID: 18053456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The federal regulation of prescription drug advertising and promotion.
    Kessler DA; Pines WL
    JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'At-risk' individuals' responses to direct to consumer advertising of prescription drugs: a nationally representative cross-sectional study.
    Khalil Zadeh N; Robertson K; Green JA
    BMJ Open; 2017 Dec; 7(12):e017865. PubMed ID: 29217723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Prescription Drug Ads Tell Consumers Enough About Benefits and Side Effects? Results From the Health Information National Trends Survey, Fourth Administration.
    Sullivan HW; Campbell M
    J Health Commun; 2015; 20(12):1391-6. PubMed ID: 26120940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning to Spot False or Misleading Prescription Drug Promotion.
    Aschenbrenner DS
    Am J Nurs; 2020 Oct; 120(10):23. PubMed ID: 32976147
    [No Abstract]   [Full Text] [Related]  

  • 16. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT; Duhamel LM; Dievler A; Price R
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Digital Video Advertising Increase Population-Level Reach of Multimedia Campaigns? Evidence From the 2013 Tips From Former Smokers Campaign.
    Davis KC; Shafer PR; Rodes R; Kim A; Hansen H; Patel D; Coln C; Beistle D
    J Med Internet Res; 2016 Sep; 18(9):e235. PubMed ID: 27627853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-to-consumer advertising of prescription drugs.
    Frosch DL; Grande D
    LDI Issue Brief; 2010; 15(3):1-4. PubMed ID: 20469541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Ambulatory Medical Care Survey: 2001 summary.
    Cherry DK; Burt CW; Woodwell DA
    Adv Data; 2003 Aug; (337):1-44. PubMed ID: 12924075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants.
    Ehrenpreis ED; Sifuentes H; Ehrenpreis JE; Smith ZL; Marshall ML
    Expert Opin Drug Saf; 2012 Mar; 11(2):177-83. PubMed ID: 22316142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.